Business
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
Guardant360 CDx test is now covered under UHC commercial policies for all FDA-approved biomarker confirmation indications in patients with advanced or
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nGuardant360 CDx test is now covered under UHC commercial policies for all FDA-approved biomarker confirmation indications in patients with advanced or metastatic breast or non-small cell lung cancer\n\n\nNation’s largest health insurer now covers Guardant360 CDx liquid biopsy for comprehensive genomic profiling for all enrolled patients\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that UnitedHealthcare (UHC) now covers the Guardant360® CDx liquid biopsy test for patients enrolled in its commercial policies for all FDA-approved companion diagnostic indications. The test is used by oncologists as a companion diagnostic to assess if patients are eligible for a targeted therapy for advanced or metastatic breast or non-small cell lung cancer (NSCLC).\n\nThe Guardant360 CDx test was the first blood test approved by the FDA for comprehensive genomic profiling for all solid tumors, and it is now FDA-approved as a companion diagnostic test for four targeted therapies in NSCLC and one in advanced breast cancer. In December 2019, Guardant360 became the first liquid biopsy to be broadly covered by Medicare for use across the vast majority of advanced solid tumors. The new policy coverage by UnitedHealthcare is in addition to existing coverage of the Guardant360 CDx test under UHC Medicare Advantage policies for comprehensive genomic profiling of all solid tumors.\n\n“We are pleased that UnitedHealthcare has taken this important step to make comprehensive genomic profiling more accessible to patients with advanced lung and breast cancer,” said Helmy Eltoukhy, Guardant Health co-CEO. “The biomarker identification available through the Guardant360 CDx blood test can enable oncologists to quickly identify patients who may benefit from a therapy targeted to their specific type of mutation to help improve their outcomes. We believe this important decision will help expand patient access to genomic profiling across additional tumor types and healthcare plans in the coming years.”\n\nThis year, an estimated 236,740 adults in the U.S. will be diagnosed with lung cancer, which is the leading cause of cancer death worldwide.1 Non-small cell lung cancer, the most common type in the U.S., represents about 82% of all lung cancer.2 Worldwide, female breast cancer ...